The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.本揭露涉及編碼VEGF-A多肽的經修飾RNA分子和包含該經修飾RNA之配製物。本揭露的多方面還涉及包含該經修飾RNA的配製物的製備和在治療患有對VEGF-A療法有反應的疾病的受試者中之用途。